Navigation Links
First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
Date:1/23/2012

esults may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, ability to obtain additional capital to support its planned operations and financial obligations, dependence on patents and proprietary rights,  and protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010, and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts For Verenium:

Kelly Lindenboom                             
'/>"/>


SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
2. Waters and NIBRT Complete Work on Worlds First UPLC Glycan Database
3. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
4. First Choice Rehabilitation Specialists Joins Select Medical
5. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
6. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
7. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
8. Amgen Announces 2012 First Quarter Dividend
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
11. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quorum Review IRB, the industry ... large clinical trials called Quick Step™ . The offering ... address the research industry’s need for seamless study start-up with ... available for studies planning 50 or more North American investigator ... North American site count of 80 or more. Qualifying studies ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
(Date:7/21/2014)... IL (PRWEB) July 21, 2014 ... and simple programming, the new Cole-Parmer® Digital ... is easy to operate for automated process ... for hands-free dispensing. The batch count function counts ... volume or totalizer tracks amount dispensed across multiple ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... MOUNTAIN VIEW, Calif., Feb. 25 Alexza,Pharmaceuticals, ... that it has initiated,its first Phase 3 ... an inhalation product candidate being developed for ... schizophrenia or bipolar disorder. Alexza,believes the novel, ...
... t2cure, a clinical,stage biopharmaceutical company developing novel regenerative ... it has appointed,Dr. Petra Rueck Head of Clinical ... join our company", said Manfred Ruediger,CEO of t2cure. ... be of critical importance to t2cure as we ...
... SAN DIEGO, Feb. 25 Speid & Associates, ... is hosting,a six session Webinar series on diabetes ... and April. Speakers will include former Food and,Drug ... Lipicky, as,well as a distinguished list of other ...
Cached Biology Technology:Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2
(Date:7/22/2014)... Institute of Standards and Technology (NIST), working with ... technique for analyzing biological cells and tissues based ... technique is an advanced form of the widely ... signals that are 10,000 times stronger than obtained ... than obtained from comparable "coherent Raman" instruments, and ...
(Date:7/22/2014)... commercial diet programs and pills, the Weight Watchers program ... the money. The Jenny Craig regimen generated the greatest ... tested, according to researchers at Duke-National University of Singapore ... the June issue of the journal Obesity , ... per dollar spent as insurance carriers consider coverage for ...
(Date:7/22/2014)... Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor ... New Orleans School of Nursing, contributed samples used ... material associated with schizophrenia and also suggesting a ... The study, Biological insights from 108 schizophrenia-associated genetic ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... of an embryonic stem cell, which has the potential to ... complex interaction of genes, proteins that bind DNA, and molecules ... paper, biologists from MIT and the University of California at ... of stem cells into mature heart cells. The study, the ...
... ultrasound waves, MIT engineers have found a way to ... drug delivery more efficient. This technology could pave the ... to the researchers. "This could be used for ... systemic drugs and proteins such as insulin, as ...
... Alps that are not native to that region? Which ... How big a threat will they become to local ... today by the European Commission,s in-house science service, the ... answering these and other questions related to 16 000 ...
Cached Biology News:Probing matters of the heart 2Probing matters of the heart 3Getting (drugs) under your skin 2Getting (drugs) under your skin 3Environment: Pooling information to combat the threat of alien species in Europe 2Environment: Pooling information to combat the threat of alien species in Europe 3
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Biology Products: